Clinical trials: Glucagon
Type2 Diabetes
Effect of GIP After a Meal in Patients With Type 2 Diabetes
The aim of this study is to investigate the effects of antagonising GIP after a meal on plasma levels of glucagon. 10 participants are going through four experimental days each, where they ingest a meal and afterwards receive…
- Trial name
- GA-7 (NCT03702660)
- Testing
- GIP(3-30)NH2, Peripheral venous cannulation, GLP-1
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes Mellitus, Type 2, Diabetes
The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
The aim of this clinical trial is to assess and compare the effect of insulin detemir in combination with liraglutide and metformin versus insulin detemir in combination with insulin aspart and metformin in subjects with very…
- Trial name
- SIMPLE (NCT01966978)
- Testing
- Metformin, Detemir, Liraglutide
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- University of Texas Southwestern Medical Center
Obesity
Location of GLP-1 Release
Background: Physicians do not have a unified, scientifically tested theory of causation for obesity and its comorbidities, nor do they have explanations for the mechanics of the metabolic/bariatric surgery procedures.
- Trial name
- NCT02036710
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Hypoglycemia
Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D
This study is a randomized, placebo-controlled, double-blind, 2-treatment, 2-period, crossover comparison in a clinical research center (CRC) setting, followed by a randomized, placebo-controlled, double-blinded, 2-arm parallel…
- Trial name
- NCT03841526
- Testing
- Glucagon RTU Injection With Insulin Pump Reduction, Vehicle for Glucagon RTU Injection With Insulin Pump Reduction, Glugaon RTU Injection Without Insulin Pump Reduction
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Xeris Pharmaceuticals
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or…
- Trial name
- SURPASS-6 (NCT04537923)
- Testing
- Tirzepatide, Insulin Lispro (U100)
- Where
- 135 sites in United States, Argentina and 14 more
- Volunteers
- 1,428 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Glucagon-like Peptide (GLP) Utilization and Safety
This study will assess the utilization patterns (adherence, source of the index antidiabetic agent (ADA) and treatment modification) of the marketed glucagon-like peptide-1 (GLP-1) receptor agonists (exenatide and liraglutide)…
- Trial name
- NCT01767389
- Testing
- The GLP-1 receptor agonist users, DPP-4 inhibitor users, Other ADA users
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Obesity
Hydrogen-rich Water and Appetite in Obesity
The main goal of this study is to investigate how dihydrogen supplementation impacts body composition, appetite, quality of life specific to obesity, and levels of the hormone GLP-1 in men and women with obesity.
- Trial name
- HYDRAPPET (NCT06722326)
- Testing
- Dietary Supplement: Hydrogen-rich water, Dietary Supplement: Control water
- Where
- Serbia
- Volunteers
- 36 people
- Sponsor
- University of Novi Sad, Faculty of Sport and Physical Education
Irritable Bowel Syndrome, Obesity
Moderate Continuous Versus High Interval Intensity Training on Gut Dysbiosis and GLP1 Hormone in IBS
investigating the response of gut bacteria via measuring short chain fatty acids and Glucagon like peptide hormone to two different modes of exercises in pre-diabetic, obese patients with irritable bowel syndrome.
- Conditions
- Irritable Bowel Syndrome, Obesity, Dysbiosis
- Trial name
- NCT06408610
- Testing
- moderate intensity continuous training
- Where
- 2 sites in Egypt
- Volunteers
- 66 people
- Sponsor
- Cairo University
Vagotomy, Truncal
Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects
The aim of this study is to investigate the role of transmission via the vagal nerve for the effect of glucose and Glucagon-like peptide-1 (GLP-1) in respect to insulin secretion.
- Trial name
- NCT01176760
- Testing
- Dipeptidyl peptidase 4 (DPP 4) inhibitor, oral glucose
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 2 Diabetes
Study on Lixisenatide and Counterregulation to Hypoglycemia
In hypoglycemia, there is a counterregulation to restore glucose levels. An important part of this counterregulation is the release of the hormone glucagon.
- Trial name
- NCT02020629
- Testing
- Lixisenatide
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Lund University
Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).
Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)
Myocardial infarction (MI) causes loss of myocytes and may lead to loss of ventricular function, morbidity and mortality. The most effective therapy is early reperfusion of the ischemic myocardium by percutaneous coronary…
- Trial name
- EXAMI (NCT01254123)
- Testing
- Exenatide infusion
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Amsterdam UMC, location VUmc
Hypoglycemia, Diabetes Mellitus, Type 1
Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics
This is a blinded, randomized crossover study to compare the safety and efficacy of G-Pen (glucagon injection) to Lilly Glucagon (glucagon for injection [rDNA origin]) for hypoglycemia rescue of adult patients with type 1…
- Trial name
- NCT02656069
- Testing
- G-Pen (glucagon injection), Lilly Glucagon (glucagon injection [rDNA origin])
- Where
- 7 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Xeris Pharmaceuticals
Type 2 Diabetes
n-3 Fatty Acid Infusion and Type 2 Diabetes
The purpose of this experimental study is to investigate whether an acute lipid infusion added marine n-3 fatty acids produces effects on insulin sensitivity in subjects with type 2 diabetes, when compared with an acute lipid…
- Trial name
- NCT00829569
- Testing
- Intralipid +/- Omegaven
- Where
- Norway
- Volunteers
- 11 people
- Sponsor
- St. Olavs Hospital
Glucose Metabolism Disorders, Endocrine or Metabolic Disease
Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?
Infusion of glucagon-like peptide 2 (GLP-2) during euglycaemia, hypoglycaemia and hyperglycaemia and evaluation of the effect on glucagon secretion in healthy subjects.
- Trial name
- GLANCE (NCT03954873)
- Testing
- Glucagon-like peptide 2, Saline, Glucose
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes After Total Pancreatectomy
Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion
Glucagon is a 29-amino acid peptide hormone of essential importance for glucose homeostasis. Hitherto glucagon has been believed to be secreted only from the pancreas, but recent studies show that glucagon is also secreted from…
- Trial name
- Px-Meal (NCT04061473)
- Testing
- Sitagliptin 100mg, Empagliflozin 25 MG
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes Mellitus, Type 1
Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients
This is a sequential efficacy and safety study in pediatric patients with type 1 diabetes. Subjects will be administered insulin to induce a low normal glycemic state and will then receive an age-appropriate dose of G-Pen…
- Trial name
- NCT03091673
- Testing
- Glucagon
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Xeris Pharmaceuticals
Type 2 Diabetes Mellitus
Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus
The purpose of this study is to confirm the mechanism of reduced response to DPP-4 inhibitor in some patients with type 2 diabetes and evaluate appropriate patients to treat with DPP-4 inhibitor
- Trial name
- NCT01449747
- Testing
- Sitagliptin
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- The Catholic University of Korea
Healthy
The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans
The purpose of this research is to help understand the relative importance of changes in insulin secretion (which lowers glucose) and changes in glucagon (which raises glucose) to regulate metabolism and the body's ability to…
- Trial name
- NCT04461015
- Testing
- 0.4mU Insulin followed by withdrawal period followed by 0.8mU study, 0.8mU Insulin followed by withdrawal period followed by 0.4mU study
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Adrian Vella